When it comes to complex diseases like cancer, “early detection” remains one of the most critical factors in determining the chances of recovery. Many studies have pointed out that most cancers may not exhibit noticeable symptoms in their early stages and can remain dormant within the body for years. This makes “early screening and early warning” a key issue.

Cancer risk is closely related to the molecular environment within the body.

While traditional screening methods, such as imaging tests or tumor markers, still hold significant value, they have limitations in identifying molecular changes at the early stages. RGCC’s Onco-D-clare test offers a more advanced support system for this purpose. It is not a diagnostic tool for cancer but rather a screening method that analyzes blood samples for molecular and genetic expression trends related to cancer risks.

Onco-D-clare: Targeting Molecular Changes That Have Not Yet Manifested

Onco-D-clare detects the expression of 92 genes related to cancer, including critical pathways involved in cell proliferation, DNA repair, and oxidative stress. This analysis helps assess an individual’s potential cancer risk, providing insight into lifestyle adjustments, nutritional strategies, or further testing.

Who Should Consider This Test?

Onco-D-clare is particularly suitable for individuals who:

• Have a family history of cancer or a high-risk background
• Have been exposed to harmful environmental factors (e.g., heavy metals, pollutants) for an extended period
• Are proactive about their long-term health and wish to use molecular data to support their health management

This is a “predictive” screening tool designed to help individuals understand their potential risk dynamics before symptoms appear.

Its Role in Cancer Care

It’s important to note that Onco-D-clare is not meant to replace medical diagnosis but rather serves as an auxiliary screening tool, offering a more comprehensive basis for integrated evaluation and proactive care. As personalized medicine continues to evolve, molecular-level screenings like these are gradually being integrated into modern health management systems.

References:

1. RGCC Group. (2023). Onco-D-clare Test – Gene Expression Analysis for Cancer Susceptibility.
2. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.
3. Vineis, P., & Wild, C. P. (2014). Global cancer patterns: causes and prevention. The Lancet, 383(9916), 549–557.
4. Bréchot, C. (2019). New frontiers in cancer detection using blood-based biomarkers. Nature Reviews Clinical Oncology, 16(6), 333–334.

Medical Disclaimer:

The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.